High purchase price is the first obstacle. 2025 market data shows a 12 % average price premium for “non‑GMP‑certified” intermediates, eroding margins for mid‑size biotech firms.
Inconsistent purity leads to batch‑to‑batch variability, forcing extra analytical work and jeopardizing FDA filings. A recent survey of 87 U.S. pharmaceutical developers revealed that 38 % experienced >0.2 % impurity spikes in outsourced intermediates.
Slow lead times – many suppliers quote 6‑8 weeks for 5 kg batches, while market pressure demands <3 weeks to stay competitive in GLP‑1 analog pipelines.
Expensive shipping & customs delays. Freight from East‑Asia often incurs >$2,500 per container, plus unpredictable clearance times that add 1‑2 weeks of downtime.
Regulatory uncertainty. Without clear documentation (DMF, FDA‑accepted certificates), your product registration may be stalled, costing up to $150 k per submission.
| Parameter | Specification |
|---|---|
| CAS No. | 1295648‑76‑8 |
| Chemical Name | Semaglutide Intermediate (Acetylated peptide) |
| Molecular Formula | C187H291N45O59S |
| Molecular Weight | 4113.64 g mol⁻¹ |
| Purity (HPLC) | ≥99.9 % (≤0.1 % related impurities) |
| Appearance | White to off‑white lyophilized powder |
| Solubility | Soluble in water (10 mg mL⁻¹) and 0.1 % acetic acid |
| Stability | Stable ≥24 months at –20 °C (sealed) |
| Packaging | HDPE bottles (≤5 kg) or bulk containers (≤25 kg) |
| Compliance | GMP, ISO 9001, FDA‑registered, CE‑marked |
GLP‑1 analog R&D: A mid‑size biotech in Boston reduced its pre‑clinical material cost by **28 %** after switching to our Semaglutide intermediate, enabling a 3‑month acceleration in IND filing.
CAS-1188328-37-1-Selumetinib-Intermediate CAS-1093241-16-7-Semaglutide-Side-Chain CAS-108-70-3-1,3,5-Trichlorobenzene CAS-124447-81-0-Semaglutide-Side-Chain
Custom formulation projects: Our ODM team delivered a patented lipid‑nanoparticle‑encapsulated Semaglutide precursor within 10 days, supporting a rapid‑go‑to‑market strategy for a US‑based specialty pharma.
Regulatory submission support: The provided GMP batch records and DMF excerpts were accepted without comment by the FDA’s CDER, cutting review cycles by an average of **15 days**.
The standard MOQ is **1 kg** for research‑grade material. For GMP‑certified bulk, the MOQ starts at **5 kg** (customizable upon request).
Yes. Our OEM/ODM team can produce acetate, hydrochloride, or free‑base forms, and tailor particle size from **≤10 µm** to **≥100 µm** based on your formulation needs.

Every batch is accompanied by a full **Certificate of Analysis (COA)**, **DMF excerpt**, GMP audit report, and chain‑of‑custody documentation that meet FDA CFR 21 Part 210/211 requirements.
We offer **express air freight (48‑72 h)**, **temperature‑controlled courier**, and **DHL/UPS priority** services. All shipments are packaged in compliance with IATA regulations for peptide powders.
Absolutely. We can ship **up to 100 mg** of research‑grade sample free of charge (shipping cost reimbursed) after a short NDA is signed.
Our technical service team provides 24/7 email support, on‑site virtual QC consultation, and a **money‑back guarantee** if the product fails to meet the agreed specifications.
Act now – our current production slot for 2026 Q3 fills within 48 hours. Secure your supply chain advantage today.
Request Quote & Free SampleOr call us now: +86 199 4383 0844
Emily R., Senior Procurement – “The sample arrived within 2 days, and the COA matched the promised 99.92 % purity. We placed a 10 kg order the same week.”
Mark T., VP of R&D – “Fast delivery and clear documentation saved us 3 weeks in our IND timeline. The OEM salt‑form work was flawless.”
Laura K., Operations Manager – “Cost reduction of 22 % allowed us to allocate budget to later‑stage trials without compromising quality.”
Trusted by Global Leaders
What Our Clients Say
Compliance & Certifications